TY - JOUR
T1 - Rational design of HIV vaccine and microbicides: report of the EUROPRISE annual conference
AU - Wahren, Britta
AU - Biswas, Priscilla
AU - Borggren, Marie
AU - Coleman, Adam
AU - Da Costa, Kelly
AU - De Haes, Winni
AU - Dieltjens, Tessa
AU - Dispinseri, Stefania
AU - Grupping, Katrijn
AU - Hallengard, David
AU - Hornig, Julia
AU - Klein, Katja
AU - Mainetti, Lara
AU - Palma, Paolo
AU - Reudelsterz, Marc
AU - Seifried, Janna
AU - Selhorst, Philippe
AU - Skold, Annette
AU - van Gils, Marit J.
AU - Weber, Caroline
AU - Shattock, Robin
AU - Scarlatti, Gabriella
PY - 2010
Y1 - 2010
N2 - EUROPRISE is a Network of Excellence sponsored from 2007 to 2011 by the European Commission within the 6th Framework Program. The Network encompasses a wide portfolio of activities ranging from an integrated research program in the field of HIV vaccines and microbicides to training, dissemination and advocacy. The research program covers the whole pipeline of vaccine and microbicide development from discovery to early clinical trials. The Network is composed of 58 partners representing more than 65 institutions from 13 European countries; it also includes three major pharmaceutical companies (GlaxoSmithKline, Novartis and Sanofi-Pasteur) involved in HIV microbicide and vaccine research. The Network displays a dedicated and informative web page: http://www.europrise.org. Finally, a distinguishing trait of EUROPRISE is its PhD School of students from across Europe, a unique example in the world of science aimed at spreading excellence through training. EUROPRISE held its second annual conference in Budapest in November, 2009. The conference had 143 participants and their presentations covered aspects of vaccine and microbicide research, development and discovery. Since training is a major task of the Network, the students of the EUROPRISE PhD program summarized certain presentations and their view of the conference in this paper.
AB - EUROPRISE is a Network of Excellence sponsored from 2007 to 2011 by the European Commission within the 6th Framework Program. The Network encompasses a wide portfolio of activities ranging from an integrated research program in the field of HIV vaccines and microbicides to training, dissemination and advocacy. The research program covers the whole pipeline of vaccine and microbicide development from discovery to early clinical trials. The Network is composed of 58 partners representing more than 65 institutions from 13 European countries; it also includes three major pharmaceutical companies (GlaxoSmithKline, Novartis and Sanofi-Pasteur) involved in HIV microbicide and vaccine research. The Network displays a dedicated and informative web page: http://www.europrise.org. Finally, a distinguishing trait of EUROPRISE is its PhD School of students from across Europe, a unique example in the world of science aimed at spreading excellence through training. EUROPRISE held its second annual conference in Budapest in November, 2009. The conference had 143 participants and their presentations covered aspects of vaccine and microbicide research, development and discovery. Since training is a major task of the Network, the students of the EUROPRISE PhD program summarized certain presentations and their view of the conference in this paper.
U2 - 10.1186/1479-5876-8-72
DO - 10.1186/1479-5876-8-72
M3 - Review article
C2 - 20659333
SN - 1479-5876
VL - 8
JO - Journal of Translational Medicine
JF - Journal of Translational Medicine
ER -
